Mary McFarlane

Monoclonal antibody therapeutics: history and future.

Simon J. Henderson, L. de Haan, J. Shenton, 2012, Current opinion in pharmacology.

Preclinical development of a high affinity α-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α-synuclein and attenuate α-synuclein spreading in vivo

E. Masliah, M. Spillantini, E. Rockenstein, 2019, Neurobiology of Disease.

Development of Immunoassays for the Quantitative Assessment of Amyloid-β in the Presence of Therapeutic Antibody: Application to Pre-Clinical Studies

K. Höglund, R. Narwal, M. Groves, 2015, Journal of Alzheimer's disease : JAD.

Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305.

M. Albertella, Z. Cooper, R. Christie, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

PRECLINICAL DISCOVERY AND DEVELOPMENT OF MEDI1814, A MONOCLONAL ANTIBODY SELECTIVELY TARGETING BETA-AMYLOID 42 (Aβ42)

I. Chessell, C. Lloyd, R. Narwal, 2017, Alzheimer's & Dementia.

MEDI1814 selectively reduces free Aβ42 in cerebrospinal fluid of non-clinical species and Alzheimer's disease patients.

N. Proctor, J. Dage, F. Natanegara, 2024, Alzheimer's & dementia : the journal of the Alzheimer's Association.